Routine Brain MRIs May Detect Breast Cancer Metastases Earlier

Regular brain magnetic resonance imaging (MRI) screening may detect asymptomatic brain metastases in patients with advanced HER2-positive or triple-negative breast cancer, potentially improving treatment outcomes and quality of life, according to a recent study.

Early Detection of Brain Metastases

Researchers at Yonsei Cancer Center in South Korea analyzed 112 patients with advanced HER2-positive or triple-negative breast cancer who did not exhibit neurological symptoms of brain metastasis between 2018 and 2023. MRI scans were conducted at the time of diagnosis and during subsequent lines of therapy.

Initial scans revealed brain metastases in 9.8% of patients despite the absence of symptoms. Continued screening increased the cumulative detection rate to 19.6%. Approximately 67% of patients who ultimately developed brain metastases were diagnosed before experiencing neurological symptoms. Source

Treatment and Quality of Life

Patients diagnosed with brain metastases were treated with stereotactic radiosurgery (SRS), a non-invasive radiation therapy. Cognitive assessments showed no significant decline in function before or after treatment, suggesting early intervention may help preserve quality of life.

Current Guidelines and Future Implications

Current clinical practice generally does not recommend routine brain MRI screening for advanced breast cancer patients unless they present with neurological symptoms. The study’s findings challenge this approach, particularly for high-risk subtypes like HER2-positive and triple-negative breast cancer, which are known to have a higher propensity for brain metastasis.

The researchers emphasize the need to consider regular brain MRI examinations, even in asymptomatic patients, to facilitate early detection and potentially improve treatment outcomes. Source

Understanding Breast Cancer Subtypes

Breast cancer is categorized into several subtypes based on the characteristics of the cancer cells. Key classifications include:

• Hormone-positive breast cancer: Cancer cells express hormone receptors.
• HER2-positive breast cancer: Cancer cells have a high level of HER2 protein.
• Triple-negative breast cancer: Cancer cells do not express hormone receptors or HER2.

Recent Advances in Breast Cancer Diagnostics

In related research, a team from Yonsei Cancer Center, in collaboration with the GC Genome research institute, has developed a whole-genome circulating tumor DNA (ctDNA) analysis method for diagnosing breast cancer genes through a simple blood test. Source This modern method offers a more comprehensive analysis than traditional targeted sequencing ctDNA analysis, which typically focuses on around 200 genes.

The ctDNA analysis method was found to be accurate when compared to tumor tissue DNA analysis, and researchers have developed an ‘I-Score’ to predict survival rates and treatment responsiveness. Source

Further Research

Professor Joohyuk Sohn, along with colleagues Kim Gun-min and Kim Min-hwan, are actively involved in research related to breast cancer, including studies on the association between skeletal muscle radiodensity and response to CDK4/6 inhibitors plus aromatase inhibitors in advanced breast cancer. Source